Published By : 02 Jan 2018 | Published By : QYRESEARCH
A drug current under development by the Lancaster University, that primarily targeted type II diabetic patients, has shown great potential to treat Alzheimer’s as the scientists have noted that it can reserve memory loss in mice via a triple method of action. This marks one of the first instance when triple receptor drug has been utilized to refrain the brain from degeneration.
The study promises to substantially improve the methods pertaining to the treatment of Alzheimer’s disease, according to Christian Holscher, the lead scientist, who says the drug has apparent potential to pave way to a mode of new treatment of chronic neurodegenerative disorders including Alzheimer’s, which is one of the common reasons behind growing cases of dementia, of which the cases are estimated to escalate up to two million along in the U.K. by 2051. The new drug is a combination of GIP, GLP-1, and Glucagon that act in multiple ways to shield the brain from degeneration.
First Advancement in Treatment of Alzheimer’s in Over a Decade
It must be noted that in the past decade, there have been very few to no new advancement as far as treatment of Alzheimer’s diseases in concerned and it has now become highly important that new drugs are explored to treat various types of dementia.
That being said, the triple agonist drugs has only shown its promise with mice and several other studies have raised concerns regarding the promise of the new drug in order to treat Alzheimer’s as there still is quite a lot of development work needed to be done.